Alzic 4mg Injection

Alzic 4mg Injection is primarily indicated in the treatment of osteoporosis caused by menopause or use of steroids and individuals with Glucocorticoid induced bone loss in both men an women. The medication active ingredient is Zoledronic Acid, a third generation nitrogen containing bisphosphonate with strong affinity for bone mineral. The medication is also used to high levels of calcium in people who have cancer. Strict doctor prescription is required before using this medication.

Osteoporosis

Like other medication, Alzic 4mg injection also caused side effects in some individuals but some need proper if the reaction becomes severe and unusual. Use the medication under the doctor prescription to ensure safety. Common ones include:
● Back pain
● Heatburn
● Headache
● Nausea
● Back pain
● Vomiting
● Anemia
● Diarrhea
● Musculoskeletal (bone, muscle or joint pain)

Alzic 4mg injection is given into a vein through an intravenous (IV) infusion. The correct dosage and duration are determined and administered only by a healthcare professional only. Do not skip doses and double them as this may increase the risk of side effects. Take on consistent use, as the medication takes several days to get the full benefit. Alzic Injection is a part of a treatment program that may also include changes to the diet and taking calcium or vitamin supplements.

Osteoporosis is a common disease in which the bones become weak and are likely to fracture. It mostly occurs in women after menopause. Zoledronic acid works by slowing down the cells called osteoclasts which is responsible for breaking down of the bone. Inside the osteoclasts, it blocks a key enzyme needed for their activity, making the cells weak and eventually causing them to die. This process reducing bone breakage and allows bone to become stronger.

• Salkovic-Petrisic, M., Knezovic, A., Hoyer, S., & Riederer, P. (2013). What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research. Journal of neural transmission, 120(1), 233-252.
• Lazić, R., Boras, I., Vlašić, M., Gabrić, N., & Tomić, Z. (2010). Anti-VEGF in treatment of central retinal vein occlusion. Collegium antropologicum, 34(2), 69-72.
• Pazyar, N., Yaghoobi, R., Zeynalie, M., & Vala, S. (2019). Comparison of the efficacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clinical, cosmetic and investigational dermatology, 115-122.
• Lazic, T., Riedesel, D. H., & Evans, R. B. (2003). Measurement of cardiac output by transesophageal Doppler ultrasonography in anesthetized dogs: comparison with thermodilution. Veterinary Anaesthesia and Analgesia, 30(2), 104-105.
• Komal, S., Mashhood, A. A., Farooq, M., & Qayyum, N. (2021). A comparison of efficacy of intradermal tranexamic acid with topical 20% azelaic acid in the treatment of melasma. Pakistan Armed Forces Medical Journal, (2), 494.